Structure Loaded Vacuum Laser-Driven Particle Acceleration Experiments at SLAC

We present an overview of the future laser-driven particle acceleration experiments. These will be carried out at the E163 facility at SLAC. Our objectives include a reconfirmation of the proof-of-principle experiment, a staged buncher laser-accelerator experiment, and longer-term future experiments that employ dielectric laser-accelerator microstructures

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

Background Individuals with rare kidney diseases account for 5–10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure. Methods People aged 0–96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan–Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window). Findings Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9–16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p<0·0001), but better survival rates (standardised mortality ratio 0·42 [95% CI 0·32–0·52]; p<0·0001). Median age at kidney failure, median age at death, time from start of dialysis to death, time from diagnosis to eGFR thresholds, and therapeutic trial window all varied substantially between rare diseases. Interpretation Patients with rare kidney diseases differ from the general population of individuals with chronic kidney disease: they have higher 5-year rates of kidney failure but higher survival than other patients with chronic kidney disease stages 3–5, and so are over-represented in the cohort of patients requiring kidney replacement therapy. Addressing unmet therapeutic need for patients with rare kidney diseases could have a large beneficial effect on long-term kidney replacement therapy demand. Funding RaDaR is funded by the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity

A Laser-Driven Linear Collider: Sample Machine Parameters and Configuration

We present a design concept for an e{sup +}e{sup -} linear collider based on laser-driven dielectric accelerator structures, and discuss technical issues that must be addressed to realize such a concept. With a pulse structure that is quasi-CW, dielectric laser accelerators potentially offer reduced beamstrahlung and pair production, reduced event pileup, and much cleaner environment for high energy physics and. For multi-TeV colliders, these advantages become significant

Optical Phase Locking of Modelocked Lasers for Particle Accelerators

Particle accelerators require precise phase control of the electric field through the entire accelerator structure. Thus a future laser driven particle accelerator will require optical synchronism between the high-peak power laser sources that power the accelerator. The precise laser architecture for a laser driven particle accelerator is not determined yet, however it is clear that the ability to phase-lock independent modelocked oscillators will be of crucial importance. We report the present status on our work to demonstrate long term phaselocking between two modelocked lasers to within one degree of optical phase and describe the optical synchronization techniques that we employ

LEAP Phase II, Net Energy Gain From Laser Fields in Vacuum

The current Laser Electron Acceleration Program (LEAP) seeks to modulate the energy of an electron bunch by interaction of the electrons with a copropagating pair of crossed laser beams at 800 nm. We present an optical injector design for a LEAP cell so that it can be used to give net energy gain to an electron bunch. Unique features of the design are discussed which will allow this net energy gain and which will also provide a robust signature for the LEAP interaction